150,344 Shares in Royalty Pharma plc (NASDAQ:RPRX) Acquired by Lansforsakringar Fondforvaltning AB publ

Lansforsakringar Fondforvaltning AB publ bought a new stake in Royalty Pharma plc (NASDAQ:RPRX - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 150,344 shares of the biopharmaceutical company's stock, valued at approximately $3,835,000.

Several other institutional investors have also modified their holdings of the stock. Mackenzie Financial Corp boosted its position in Royalty Pharma by 7.0% during the fourth quarter. Mackenzie Financial Corp now owns 142,022 shares of the biopharmaceutical company's stock worth $3,623,000 after acquiring an additional 9,313 shares during the last quarter. Formidable Asset Management LLC boosted its position in Royalty Pharma by 12.9% during the fourth quarter. Formidable Asset Management LLC now owns 36,911 shares of the biopharmaceutical company's stock worth $942,000 after acquiring an additional 4,226 shares during the last quarter. GF Fund Management CO. LTD. acquired a new position in Royalty Pharma during the fourth quarter worth about $238,000. University of Texas Texas AM Investment Management Co. acquired a new position in Royalty Pharma during the fourth quarter worth about $1,219,000. Finally, Public Employees Retirement System of Ohio boosted its position in Royalty Pharma by 4.4% during the fourth quarter. Public Employees Retirement System of Ohio now owns 151,583 shares of the biopharmaceutical company's stock worth $3,867,000 after acquiring an additional 6,454 shares during the last quarter. Institutional investors and hedge funds own 54.35% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages have commented on RPRX. Wall Street Zen downgraded shares of Royalty Pharma from a "buy" rating to a "hold" rating in a research note on Tuesday, May 20th. Morgan Stanley began coverage on shares of Royalty Pharma in a research note on Friday, May 16th. They set an "overweight" rating and a $51.00 target price on the stock. Finally, Citigroup reaffirmed a "buy" rating on shares of Royalty Pharma in a research note on Friday, March 28th. Two analysts have rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, Royalty Pharma currently has a consensus rating of "Moderate Buy" and an average price target of $42.50.

Royalty Pharma Trading Up 1.2%

Shares of Royalty Pharma stock traded up $0.38 on Monday, reaching $33.26. The company had a trading volume of 4,168,567 shares, compared to its average volume of 3,528,692. The firm's 50 day moving average price is $32.34 and its two-hundred day moving average price is $30.50. The firm has a market cap of $18.70 billion, a PE ratio of 22.94, a PEG ratio of 2.31 and a beta of 0.49. Royalty Pharma plc has a 52-week low of $24.05 and a 52-week high of $34.32. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.44 and a current ratio of 1.44.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.99 by $0.07. The business had revenue of $839.00 million for the quarter, compared to the consensus estimate of $724.69 million. Royalty Pharma had a net margin of 37.94% and a return on equity of 24.40%. Sell-side analysts predict that Royalty Pharma plc will post 4.49 earnings per share for the current fiscal year.

Royalty Pharma Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Friday, May 16th will be paid a dividend of $0.22 per share. This represents a $0.88 annualized dividend and a yield of 2.65%. The ex-dividend date is Friday, May 16th. Royalty Pharma's payout ratio is currently 47.57%.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.